Jaguar Health Declares Special Convertible Preferred Stock Dividend, Signaling Significant Future Dilution
JAGX sits 18% above its 52-week low of $0.56.
Summary
Jaguar Health announced a special one-time dividend of Series O Convertible Preferred Stock, intended to protect existing shareholders from future dilution but carrying substantial risk of significant dilution upon conversion.
Key Events · Financing and Capital Events · JAGX
-
Special Stock Dividend Declared
The Board declared a one-time dividend of Series O Convertible Preferred Stock for each share of common stock and certain eligible warrants outstanding as of March 2, 2026.
-
Variable Conversion Terms
The Series O Preferred Stock is convertible into common stock at the company's discretion or automatically by December 31, 2026, with a variable conversion ratio based on the common stock's market price at conversion.
-
Significant Dilution Risk Highlighted
The filing explicitly warns that conversion could result in the issuance of a substantial number of common shares, potentially causing significant dilution for stockholders, especially those who do not receive the dividend.
-
Non-Transferable and Unlisted
The Series O Preferred Stock is not transferable and will not be listed on any exchange, limiting liquidity and market value for recipients.
Analysis · JAGX · Life Sciences
Jaguar Health's declaration of a special one-time dividend of Series O Convertible Preferred Stock, while framed as a measure to protect existing shareholders from dilution, introduces a new and potentially severe dilutive mechanism. The Series O Preferred Stock is designed to convert into common stock at a variable ratio tied to the market price, with the company's own risk factors illustrating scenarios where this could lead to over 80% dilution of outstanding common stock. This move signals the company's ongoing financial distress and its need to manage substantial debt, as also evidenced by recent financing activities. The non-transferable and unlisted nature of the preferred stock further complicates its value for recipients. Investors should be aware of the significant overhang this convertible preferred stock creates, as its future conversion could substantially increase the number of common shares outstanding, negatively impacting the stock price and existing shareholder value. This action is part of a pattern of financing and debt management for a company facing recurring losses and Nasdaq listing challenges.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 42% of the 419 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $0.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.56 to $25.75. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.